Screening of an FDA-approved drug library reveals MEK1/2 inhibitors block production of osteoarthritis mediators in activated human chondrocytes and synovial fibroblasts.

Detalles Bibliográficos
Publicado en:Osteoarthritis & Cartilage Vol. 34; no. 6; pp. 806 - 819
Autores principales: Coryell, Philip R., Fernandez Davila, Jorge G., Yanke, Adam B., Pearce, Kenneth H., Loeser, Richard F.
Formato: Journal Article
Publicado: Elsevier B.V. Jun2026
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=193863893&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 193863893
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        10634584
        NZV
      jtl: Osteoarthritis & Cartilage
      issn: 10634584
      maglogo: N
    pubinfo:
      dt: Jun2026
      vid: 34
      iid: 6
      pid: 467
      pub: Elsevier B.V.
      place: New York, New York
    artinfo:
      ui:
        193863893
        10.1016/j.joca.2026.03.116
        193863893
      ppf: 806
      ppct: 13
      formats:
      tig:
        atl: Screening of an FDA-approved drug library reveals MEK1/2 inhibitors block production of osteoarthritis mediators in activated human chondrocytes and synovial fibroblasts.
      aug:
        au:
          Coryell, Philip R.
          Fernandez Davila, Jorge G.
          Yanke, Adam B.
          Pearce, Kenneth H.
          Loeser, Richard F.
        affil: Thurston Arthritis Research Center, School of Medicine, University of North Carolina, Chapel Hill, NC, USA
      sug:
      pubtype: Academic Journal
      doctype: Journal Article
      ougenre: Article
      ab:
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N